Logistic regression model 2 for the positivity rate
| ALK | EGFR | PD-L1 | ||||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Sample type* (ref. biopsy) | ||||||
| Cell block | 0.74 (0.30 to 1.56) | 0.474 | 0.86 (0.58 to 1.23) | 0.417 | 1.01 (0.74 to 1.40) | 0.931 |
| FNA | 1.82 (0.60 to 4.52) | 0.237 | 0.58 (0.35 to 0.93) | 0.029 | 0.78 (0.25 to 2.38) | 0.665 |
| Surgical piece | 1.15 (0.63 to 2.01) | 0.633 | 0.80 (0.58 to 1.08) | 0.156 | 0.80 (0.62 to 1.02) | 0.075 |
| Blood | – | – | 0.42 (0.22 to 0.76) | 0.005 | – | – |
| Others | 1.52 (0.62 to 3.25) | 0.313 | 1.22 (0.78 to 1.87) | 0.366 | 1.20 (0.75 to 1.93) | 0.457 |
| NSCLC-NOS (ref. adenocarcinoma) | 0.77 (0.29 to 1,66) | 0.547 | 0.15 (0.06 to 0.31) | <0.001 | 1.19 (0.86 to 1.65) | 0.289 |
| Result ALK: positive | – | – | 0.10 (0.01 to 0.47) | 0.025 | 1.63 (0.94 to 2.86) | 0.084 |
| Result ALK: missing | – | – | 4.12 (2.97 to 5.72) | 0.000 | 1.21 (0.83 to 1.77) | 0.318 |
| Result EGFR: positive | 0.10 (0.01 to 0.45) | 0.022 | – | – | 0.70 (0.51 to 0.97) | 0.035 |
| Result EGFR: missing | 0.76 (0.18 to 2.10) | 0.652 | – | – | 1.38 (0.95 to 2.01) | 0.089 |
| Result PD-L1: positive | 1.61 (0.94 to 2.83) | 0.088 | 0.71 (0.51 to 0.98) | 0.039 | – | – |
| Result PD-L1: missing | 1.22 (0.69 to 2.19) | 0.501 | 1.07 (0.80 to 1.43) | 0.651 | – | – |
| Result ROS1: positive | – | – | 2.03 (0.80 to 4.54) | 0.103 | 0.97 (0.41 to 2.29) | 0.952 |
| Result ROS1: missing | – | – | 0.91 (0.68 to 1.20) | 0.498 | 0.88 (0.70 to 1.11) | 0.274 |
| Hosmer-Lemeshow, p value | 0.68 | 0.904 | 0.929 | |||
| AUROC (95% CI) | 0.613 (0.555 to 0.672) | 0.679 (0.650 to 0.708) | 0.562 (0.536 to 0.587) | |||
The results of the Hosmer-Lemeshow test and the AUROC are in italics to differentiate them from the ORs.
*Category ‘others’ includes blood samples for ALK and PD-L1 models.
ALK, anaplastic lymphoma kinase; AUROC, area under receiver operating characteristic curve; EGFR, epidermal growth factor receptor; FNPA, fine-needle aspiration; NSCLC-NOS, non-smallcell lung cancer–not otherwise specified; PD-L1, programmed death ligand-1; ref., reference; ROS1, c-ros oncogene 1.